Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key bre ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Tango Therapeutics (TNGX) stock plunged 28% Wednesday after the company announced updates on several drug candidates and released its Q3 earnings report. Read more here.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...

INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. “Lilly had another strong growth quarter in Q3, with ...

A council plans on battling “the plague” of shopping trolleys dumped in its rivers and streets by hitting supermarkets harder in the pocket. A wildlife reserve visitor centre has been damaged ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings. The American Society of Clinical Oncology ...

Previously, we could only use abemaciclib, and now we have a new ribociclib. If a patient is unable to tolerate abemaciclib, we can try ribociclib. The ribociclib population is more broad ...